<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102946</url>
  </required_header>
  <id_info>
    <org_study_id>IRaHi</org_study_id>
    <nct_id>NCT01102946</nct_id>
  </id_info>
  <brief_title>Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy</brief_title>
  <acronym>IRaHi</acronym>
  <official_title>Panretinal Photocoagulation Versus Panretinal Photocoagulation Plus Intravitreous Ranibizumab for High Risk Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of panretinal photocoagulation plus
      intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic
      retinopathy in terms of changes in visual acuity and neovascularization area.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescein leakage area (mm2)</measure>
    <time_frame>Week 48 after inclusion in the study</time_frame>
    <description>Neovascularization area measured during fluorescein agiography middle phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMT</measure>
    <time_frame>Week 48 after inclusion in the study</time_frame>
    <description>Macular thickness measured with Stratus OCT protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LogMAR BCVA</measure>
    <time_frame>Week 48 after inclusion in the study</time_frame>
    <description>LogMAR best corrected visual acuity measured with ETDRS charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retina mid periphery visual field sensitivity change</measure>
    <time_frame>Week 48 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rod pathway integrity and oscillatory potential amplitudes</measure>
    <time_frame>Week 48 after inclusion in the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Neovascularization</condition>
  <arm_group>
    <arm_group_label>PRP plus ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will only be submitted to panretinal photocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab (Lucentis), intravitreal injections of 0.05ml</description>
    <arm_group_label>PRP plus ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Panretinal Photocoagulation</intervention_name>
    <description>Panretinal photocoagulation with green laser according to ETDRS</description>
    <arm_group_label>PRP plus ranibizumab</arm_group_label>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  High risk proliferative diabetic retinopathy

          -  Visual acuity ≥ 20/800

          -  No previous laser treatment for diabetic retinopathy

        Exclusion Criteria:

          -  Previous pars plana vitrectomy

          -  Systemic thrombo-embolic events

          -  Uncontrolled systemic hypertension

          -  Conditions avoiding adequated documentation

          -  Previous eye surgery in the last 6 months before inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of São Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21726427</url>
    <description>article on Pubmed</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rodrigo Jorge</name_title>
    <organization>University of São Paulo</organization>
  </responsible_party>
  <keyword>proliferative diabetic retinopathy</keyword>
  <keyword>retinal neovascularization</keyword>
  <keyword>Angiogenesis Inhibitors</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Retinal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

